V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240014512 | 240008871 | 1.54 | 60.5 | Palliative (P) | 2016-02-06 | 2016-02-06 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | 240021767 | NAB-PACLITAXEL |
| 240014513 | 240008872 | 1.66 | 52.5 | null | null | 2016-09-18 | Carboplatin + Topotecan | N | null | 240021787 | LENALIDOMIDE + RITUXIMAB |
| 240014514 | 240008873 | 1.53 | 64.3 | Curative (C) | 2017-11-24 | 2017-12-21 | Carboplatin + Topotecan | N | N | 240021810 | IVAC |
| 240014516 | 240008876 | null | 60.1 | Disease modification (D) | 2014-06-17 | 2014-06-17 | Fludarabine + Melphalan RIC Allo | N | null | 240022028 | PONATINIB |
| 240014517 | 240008878 | null | null | Curative (C) | 2015-07-17 | 2015-07-17 | VEDex | N | N | 240022032 | GEMCITABINE + IFOSFAMIDE + VINORELBINE |
| 240014518 | 240008880 | 1.54 | 65.3 | Palliative (P) | 2017-08-07 | 2017-08-20 | ICE (no GCSF) | 2 | N | 240022117 | CLOFARABINE + CYTARABINE |
| 240014519 | 240012744 | 1.8 | 67 | Disease modification (D) | 2016-04-04 | 2016-04-13 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE | N | N | 240022121 | CHOEP |
| 240014520 | 240012746 | 1.65 | 67.1 | Curative (C) | 2018-08-09 | 2018-08-12 | Liposomal Doxorubicin 40mg/m2 | N | N | 240022183 | CAV |
| 240014521 | 240008884 | 1.65 | 93.6 | Curative (C) | 2018-02-22 | 2018-05-22 | Ofatumumab Monthly | 2 | N | 240022298 | OXALIPLATIN |
| 240014522 | 240008887 | 1.65 | null | Disease modification (D) | 2013-07-25 | 2013-07-30 | VINCRISTINE | 02 | N | 240022497 | LIPOSOMAL DOXORUBICIN |
| 240014523 | 240008888 | 0 | 85 | Curative (C) | 2013-05-03 | 2013-05-03 | Etoposide oral | 2 | N | 240022512 | AML17 TRIAL |
| 240014524 | 240008891 | 1.57 | 67.9 | Palliative (P) | 2017-09-26 | 2017-09-26 | Carboplatin + Docetaxel | 02 | N | 240022526 | GEMTUZUMAB OZOGAMICIN |
| 240014525 | 240008895 | 0 | 57 | Palliative (P) | 2014-12-05 | 2014-12-07 | MABCUTE TRIAL | N | null | 240022609 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 240014526 | 240008897 | 1.7 | 79.8 | Curative (C) | 2018-04-12 | 2018-06-05 | Docetaxel + Gemcitabine (prior RT) | N | N | 240022676 | CARBOPLATIN + TOPOTECAN |
| 240014527 | 240012754 | 1.63 | 55.4 | Palliative (P) | 2017-07-28 | 2017-08-07 | RUXOLITINIB | N | N | 240022791 | IGEV R |
| 240014528 | 240008900 | 1.59 | 70.8 | Palliative (P) | 2017-06-11 | 2017-11-21 | CODOX M | N | N | 240022810 | CHOEP |
| 240014529 | 240008902 | 1.52 | 67 | Curative (C) | 2015-09-07 | 2015-09-07 | Cytarabine intrathecal | N | N | 240022832 | NAB-PACLITAXEL |
| 240014530 | 240014560 | 1.75 | 103 | Palliative (P) | 2017-06-02 | 2017-06-04 | AML17 TRIAL | 02 | N | 240022998 | ICE-R |
| 240014531 | 240008905 | 1.69 | null | Palliative (P) | null | 2015-11-06 | Irinotecan + Modified De Gramont | null | null | 240023081 | ABVD R |
| 240014532 | 240008907 | null | 81.3 | null | null | 2017-06-27 | ESHAP R | null | null | 240023140 | CARBOPLATIN + RT |
| 240014533 | 240008908 | 1.71 | 81.5 | Curative (C) | 2018-02-09 | 2018-02-10 | Triple Intrathecal | 2 | N | 240023188 | CYTARABINE HIGH DOSE |
| 240014534 | 240008910 | 1.57 | null | Curative (C) | 2014-02-11 | 2014-04-09 | R-GEM-P | N | N | 240023200 | DABRAFENIB + TRAMETINIB |
| 240014535 | 240008911 | 1.7 | 83 | Adjuvant (A) | 2014-10-29 | 2014-11-24 | RCEOP | N | N | 240023318 | PEMBROLIZUMAB |
| 240014536 | 240008913 | 1.81 | 77.1 | Curative (C) | 2017-11-15 | 2017-11-15 | R CODOX M | 2 | N | 240023657 | CLADRIBINE |
| 240014537 | 240008915 | 1.65 | 55.4 | Neo-adjuvant (N) | 2018-03-02 | 2018-03-04 | Doxorubicin 75mg/m2 | N | null | 240023735 | DOXORUBICIN |
| 240014538 | 240008918 | 1.65 | 50.8 | Palliative (P) | null | 2014-10-08 | THALIDOMIDE | N | N | 240023738 | AML19 TRIAL |
| 240014539 | 240008919 | null | null | Curative (C) | 2014-12-28 | 2015-02-15 | AML16 DA 3+10 | N | null | 240023752 | FBC |
| 240014540 | 240008923 | 1.86 | 81.1 | Palliative (P) | 2014-11-10 | 2014-12-07 | ATG + Busulfan + Fludarabine | N | N | 240023933 | ENZALUTAMIDE |
| 240014541 | 240008925 | 1.6 | 68.2 | Palliative (P) | 2017-09-10 | 2017-12-30 | RCEOP | N | N | 240023933 | ICE-R |
| 240014542 | 240012772 | 1.8 | 68.2 | Palliative (P) | 2016-08-16 | 2016-08-19 | Gefitinib: Cycle 3 only (PAS) | 02 | N | 240024570 | IVAC |
| 240014543 | 240008929 | 1.66 | 46.8 | Palliative (P) | 2015-12-13 | 2016-03-21 | R-GEM-P | null | null | 240024747 | VINCRISTINE |
| 240014544 | 240008931 | null | 75.3 | Palliative (P) | 2018-07-15 | 2018-08-31 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 240025194 | CYTARABINE HIGH DOSE |
| 240014545 | 240008935 | 1.6 | null | Curative (C) | 2017-10-21 | 2017-11-24 | ATG + Busulfan + Fludarabine + Thiotepa | Y | N | 240025582 | OFATUMUMAB |
| 240014546 | 240008936 | 1.59 | 63 | Curative (C) | 2017-07-30 | 2017-07-30 | Cisplatin + Etoposide + RT | 1 | N | 240025641 | CODOX M |
| 240014547 | 240008937 | null | 103.8 | Curative (C) | 2013-10-21 | 2013-10-21 | Capecitabine + Oxaliplatin 21day | N | N | 240026056 | GEMCITABINE + PACLITAXEL |
| 240014548 | 240008940 | 1.7 | 77 | Palliative (P) | 2014-08-16 | 2014-08-18 | FLUOROURACIL + OXALIPLATIN | 02 | N | 240026078 | RCEOP |
| 240014549 | 240015474 | 1.75 | 0 | Curative (C) | 2016-01-07 | 2016-01-11 | GEM-P | N | N | 240027348 | CISPLATIN + GEMCITABINE |
| 240014550 | 240008945 | 1.63 | 54.6 | Curative (C) | 2018-10-19 | 2018-11-08 | AML17 TRIAL | N | N | 240027620 | GALLIUM TRIAL |
| 240014551 | 240012779 | 1.66 | 112.8 | Disease modification (D) | 2016-01-17 | 2016-01-17 | Ofatumumab Loading | N | N | 240027765 | GEMCITABINE + VINORELBINE |
| 240014552 | 240008946 | 1.7 | 64.35 | Palliative (P) | 2016-11-18 | 2016-11-20 | mEOC TRIAL | N | N | 240027838 | CISPLATIN + PACLITAXEL |
| 240014553 | 240008948 | null | null | Palliative (P) | 2018-04-06 | 2018-04-06 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 2 | N | 240028005 | NHL 2003 |
| 240014554 | 240008953 | null | 74.2 | Curative (C) | 2017-11-29 | 2017-12-12 | Escalated BEACOPP | N | N | 240028346 | AML17 TRIAL |
| 240014555 | 240008954 | 1.8 | 86.6 | Curative (C) | 2016-08-30 | 2016-09-03 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE | 02 | N | 240028501 | CYTARABINE INTRATHECAL |
| 240014556 | 240012784 | 1.66 | 92.6 | Curative (C) | 2018-11-02 | 2018-11-02 | NAB PACLITAXEL | N | N | 240028943 | CARBOPLATIN + TOPOTECAN |
| 240014557 | 240012785 | 1.78 | 96 | Disease modification (D) | 2017-02-10 | 2017-02-11 | Gefitinib: Cycle 3 only (PAS) | 2 | N | 240028966 | CYTARABINE + METHOTREXATE |
| 240014558 | 240008958 | 1.6 | 61 | Curative (C) | 2017-08-19 | 2017-08-21 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | N | null | 240029335 | CARBOPLATIN + VINORELBINE |
| 240014559 | 240008960 | null | 55 | Neo-adjuvant (N) | 2017-10-24 | 2017-10-24 | ICE-R (Cycle 2 onwards) | N | N | 240029688 | CAV |
| 240014560 | 240015477 | 1.85 | 82.4 | Palliative (P) | 2016-07-21 | 2016-07-26 | BEACOPP-14 | N | N | 240030162 | RCEOP |
| 240014561 | 240008964 | 1.68 | 70 | Disease modification (D) | 2014-03-21 | 2014-03-21 | BEVACIZUMAB + CARBO | N | N | 240030314 | NAB-PACLITAXEL |
| 240014562 | 240008966 | 1.83 | 73.4 | Curative (C) | 2017-03-18 | 2017-03-25 | VEDex | N | null | 240030532 | BENDAMUSTINE + THALIDOMIDE |